cowan conference, page-23

Good presentation. Earlier threads have questioned power of IMAGINE to detect differences between placebo and treatment groups. I have read through the trial design a fair few times but missed that the randomisation was in a 2:1 fashion (drug:placebo) so in fact are similar numbers of patients on drug as in the IIa trial. Plus have the advantage of 12months follow up (excluding trial extension), allowing the the statistics to 'take advantage' of the natural disease course in the placebo group (unfortunately for them, is never up). Looking forward to "late March" - still have a voice in my head screaming "buy into any retrace".